S&P Futures
4,125.25 +1.75 (+0.04%) Dow Futures
33,912.00 -22.00 (-0.06%) Nasdaq Futures
12,533.75 +18.25 (+0.15%) Russell 2000 Futures
1,964.20 -0.90 (-0.05%) Crude Oil
75.59 +1.48 (+2.00%) Gold
1,882.50 +3.00 (+0.16%)
Grifols, S.A. (G0F.F)
Chart Events
Performance Outlook
| Previous Close | 6.45 |
| Open | 6.45 |
| Bid | 6.60 x N/A |
| Ask | 7.25 x N/A |
| Day's Range | 6.45 - 6.45 |
| 52 Week Range | 3.86 - 9.60 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 8.758B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 129.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for G0F.F
Related Research
- PR Newswire
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
- PR Newswire
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor. Both changes are effective immediately.
- GlobeNewswire
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi
